Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
1. Study Shows Strong Tobacco Control Programs and Policies Can Lower Smoking Rates (Posted: 11/18/2003, Updated: 06/16/2004) - A study published today in the Journal of the National Cancer Institute provides the latest evidence that investing in state tobacco control programs can reduce smoking rates.
2. Bevacizumab (Avastin™) Improves Survival in Metastatic Colorectal Cancer (Posted: 06/01/2003, Updated: 06/14/2004) - Patients with newly diagnosed metastatic colon cancer who received the therapeutic agent bevacizumab (Avastin™) along with the chemotherapy combination known as IFL had substantially longer overall survival times than patients who received IFL but with a placebo instead of bevacizumab. With these results, bevacizumab becomes the first anti-angiogenesis agent to prove effective in a randomized Phase III trial.
3. Limited Lymph Node Removal and Stomach Cancer (Posted: 05/05/2004, Updated: 06/14/2004) - In a Dutch study, patients with stomach (gastric) cancer who were treated with more extensive surgery involving the removal of more lymph nodes did not live longer than those who received a more limited lymph node removal (dissection). The study was published online April 13, 2004, by the Journal of Clinical Oncology.
4. Oxaliplatin-Based Regimen Prolongs Survival After Colorectal Cancer Surgery (Posted: 06/01/2003, Updated: 06/14/2004) - The oxaliplatin-based chemotherapy combination known as FOLFOX significantly improved disease-free survival compared to 5-FU and leucovorin when used as adjuvant therapy (after surgery) in patients with stage II and stage III colorectal cancer.
5. Zoledronic Acid Reduces Bone Complications of Advanced Prostate Cancer (Posted: 06/21/2002, Updated: 06/14/2004) - In a study published in the October 2, 2002, issue of the Journal of the National Cancer Institute, patients with prostate cancer that had spread to the bones had fewer fractures and other bone complications when they took a new drug, zoledronic acid (also called zolendronate or Zometa®) than when they took a placebo.
1 2 3 4 Next > |